Clinical study of endoscopic mucosal resection for digestive tract early cancer and precancerous lesions treatment
Abstract
The clinical effect of endoscopic mucosal resection (EMR) on the digestive tract of early cancer and precancerous lesions was analyzed. 63 patients with early gastrointestinal cancer and precancerous lesions treated in our hospital from January 2013 to May 2015 were recruited for this study. Patients were randomly divided into the observation group (32 cases) and the control group (31 cases). The control group underwent conventional surgical treatment, while the observation group underwent EMR treatment. Both groups were observed for the clinical effect. The curative resection rate was 100.0% (P > 0.05). The postoperative complication rate in the observation group was 3.1% (1/32) and 25.8% (8/31) in the control group. The operative time for the observation group was significantly shorter than the control group (P < 0.05). Study subjects were followed up for 1 year. Both groups showed no primary tumor metastasis and recurrence (P > 0.05). EMR treatment showed good effect and significantly fewer complications in patients with early gastrointestinal cancer and precancerous lesions.References
2. Xu M, Peng Q, Zhu Y. The clinical analysis of treatment effect of EMR on digestive tract early cancer and precancerous lesions analysis. World Latest Med Info 2015; 15(10): 123–124.
3. Sun X, Wang X, Lu Z. How nova endoscopic procedures altered the diagnostic and therapeutic modality of early gastrointestinal cancer. Chin J Intern Med 2013; 33(3): 207–209.
4. Liu B, Wang F, Wang S. The efficacy of endoscopic submucosal dissection for digestive tract early cancer and precancerous lesions. J Pract Med 2015; 31(14): 2346–2348.
5. Tian K. Clinical research on the treatment effect of EMR on the treatment of gastrointestinal cancer and precancerous lesions. Chin Contin Med Edu 2015; 7(32): 58–59.
Copyright (c) 2016 Peng Huiji
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.